ArticleFrontiers in pharmacology2026
NSFC-funded Chinese materia medica research (2015-2024): achievements output, research characteristics, and evolution.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To systematically analyze the project completion status and research characteristics in the field of Chinese Materia Medica (CMM, discipline code H32) funded by the National Natural Science Foundation of China (NSFC), thereby providing a basis for optimizing the allocation of scientific research resources and adjusting funding strategies. Methods: Based on the NSFC big database system, a retrospective analysis was conducted to descriptively analyze the research output, potential translational capacity, and research characteristics of completed projects in the CMM field funded by NSFC from 2015 to 2024. Results: From 2015 to 2024, a total of 4,574 projects in the CMM field were completed, with a compound annual growth rate (CAGR) of 3.0%. The cumulative total funding was 1.86 billion RMB, with an average of 410 KRMB per project. The average research output was 6.6 items per project, and the potential patent conversion ratio was 61%. For the first time, the 19 sub-directions within the CMM field were categorized into four echelons: double-high advantage, high-output low-conversion, low-output high-conversion, and Low-Output Low-Conversion areas. Key advantage areas included CMM pharmacodynamic substances, CMM resources, and ethnic pharmacology. Disease research primarily focused on cardiovascular and cerebrovascular diseases, tumors, metabolic diseases, and neurological disorders. Technical methodologies rapidly evolved from traditional chemical analysis to multi-omics and systems biology, while research mechanisms expanded towards multi-dimensional regulatory networks. Conclusion: NSFC funding for the CMM field has been consistently stable. The discipline demonstrates an overall trajectory characterized by deepening basic research, rapid iteration of technical methods, increasing diversification of research directions, and steadily improving translational potential. These findings provide data support and decision-making references for optimizing NSFC funding strategies in the CMM field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.